Semax vs Selank
Educational comparison for newcomers. Not medical advice. Semax and Selank are often mentioned in the same breath online. They are related Russian research products, but they are not the same peptide and were developed for different clinical aims. This page helps you keep them straight without overclaiming what either can do.
Intro
Both molecules came out of Russian regulatory-peptide work at the Institute of Molecular Genetics (IMG), Russian Academy of Sciences, associated with researchers including N.F. Myasoedov and I.P. Ashmarin. Both are heptapeptides stabilized with a C-terminal Pro-Gly-Pro (PGP) motif. Both are typically discussed as intranasal medicines in Russian practice.
After that, the stories diverge: Semax is built from an adrenocorticotropic hormone (ACTH) fragment and is framed mainly as nootropic / neuroprotective; Selank is built from tuftsin (an immune-system peptide fragment) and is framed mainly as an anxiolytic.
Side-by-side at a glance
| Semax | Selank | |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) | Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) |
| Parent idea | ACTH(4–10) / ACTH(4–7) fragment + PGP tail | Tuftsin (Thr-Lys-Pro-Arg) + PGP tail |
| Usual framing | Nootropic, neuroprotective | Anxiolytic (anti-anxiety), with some nootropic / adaptive discussion |
| Russian product form | Nasal drops (e.g. 0.1%, and a 1% stroke-oriented form in literature) | Nasal drops (commonly discussed as 0.15%) |
| Russian registration era | Clinical use from mid-1990s; label registrations cited around 2011 for current 0.1% text | Registered for medical use around 2009 (per IMG-linked review) |
| Example clinical focus in Russian literature | Stroke / cerebrovascular recovery, cognitive support, optic-nerve disease | Generalized anxiety disorder, neurasthenia |
| U.S. Food and Drug Administration (FDA) / European Medicines Agency (EMA) | Not approved | Not approved |
Uncertainty flag: Popular blogs often claim clean “Semax = focus, Selank = chill” marketing slogans. Real papers are messier: both peptides touch overlapping systems (e.g. enkephalin metabolism; brain-derived neurotrophic factor (BDNF)-related findings in animals), and neither has a large modern Western pivotal trial package.
Shared scientific roots
- Same design school: Take a short natural peptide with interesting central nervous system (CNS) effects → add Pro-Gly-Pro to resist rapid breakdown → develop a nasal drug candidate.
- Same institute lineage: IMG RAS peptide pharmacology program.
- Shared biochemical curiosity: A 2001 study reported that both Semax and Selank inhibit enkephalin-degrading enzymes from human serum (in vitro), with Semax somewhat more potent than Selank in that assay: interesting mechanism overlap, not proof they do the same clinical job.
- Same visitor marketplace: Online “nootropic peptide” culture sells them side by side, which amplifies name confusion.
How Semax is usually positioned
- Chemistry: ACTH-related heptapeptide without the hormonal steroidogenic activity of full ACTH (a key design goal).
- Research themes: Learning/memory models; neuroprotection in ischemia models; upregulation of BDNF / tropomyosin receptor kinase B (TrkB) pathways in animal hippocampus work; Russian clinical series in ischemic stroke and chronic cerebrovascular disease.
- Regulatory identity in Russia: Prescription nootropic nasal medicine; discussed in essential-drugs / standards contexts (see Regulatory page).
Do not overclaim: Animal BDNF changes and Russian open-label or small controlled series are not the same as proving cognitive enhancement for healthy people worldwide.
How Selank is usually positioned
- Chemistry: Tuftsin analog heptapeptide (tuftsin itself is Thr-Lys-Pro-Arg from IgG).
- Research themes: Anxiety models; comparisons in Russian psychiatry to benzodiazepine-type agents with authors emphasizing less sedation / muscle relaxation in their framing; effects on genes linked to GABAergic neurotransmission in animal work; immunomodulatory / cytokine discussions reflecting tuftsin ancestry.
- Clinical literature example: A randomized comparative study in patients with generalized anxiety disorder and neurasthenia compared Selank with medazepam, reporting similar anxiolytic effects with additional antiasthenic / psychostimulant-type notes for Selank in that paper’s framing.
- Regulatory identity in Russia: Registered anxiolytic-oriented nasal medicine (Selank 0.15% in the 2013 IMG review narrative).
Do not overclaim: “Like a benzo without side effects” is marketing language. The peer-reviewed record is smaller and largely regional; mechanisms are still being mapped.
Mechanisms: careful, non-hype version
| Theme | Semax in the literature | Selank in the literature |
|---|---|---|
| Neurotrophins | Stronger emphasis on BDNF / nerve growth factor (NGF) expression changes (esp. animal CNS) | Also reported to affect BDNF expression in some animal hippocampus studies; less central to its “elevator pitch” |
| Anxiety circuitry | Some animal anxiolytic-like findings under stress, but not its primary clinical brand | Primary brand: anxiolysis; GABA-related gene-expression work; enkephalinase inhibition hypothesis |
| Immune angle | Discussed less as an immunomodulator drug | Tuftsin heritage → immunomodulatory / cytokine research threads |
| Clinical brand in Russia | Brain injury / ischemia / cognition / optic nerve | Generalized anxiety disorder (GAD) / neurasthenia / stress adaptation |
Uncertainty flag: Transcriptome and enzyme papers explain possible pathways; they do not by themselves establish clinical superiority for any everyday visitor goal.
Helping newcomers not confuse them
Remember the parents:
- Semax ← ACTH fragment → think “ACTH/nootropic/neuroprotect line.”
- Selank ← tuftsin → think “immune-peptide/anxiety line.”
Remember the names are not interchangeable. A vial labeled only “peptide blend” or a blog that swaps them mid-paragraph is a quality/credibility warning.
Remember geography. Both are Russian pharmaceuticals in origin. Neither is FDA/EMA-approved. Online research listings are not pharmacy equivalents.
Remember evidence limits. If a source promises guaranteed IQ boosts, stimulant replacement, or benzo replacement with zero downsides, it has left the peer-reviewed lane.
FAQs newcomers actually ask
Can they be “stacked”?
Internet forums discuss combinations constantly. That is not the same as a well-powered clinical evidence base showing additive benefit or defining safe combined use. This site does not recommend stacking.
Which one is “stronger”?
Stronger at what? They were aimed at different problems. Comparing “strength” without a shared endpoint is how confusion starts.
Are acetylated / amidated versions the same?
No. Chemical modifications change the molecule. Russian pharmacy Semax/Selank labels refer to specific registered preparations: not every analog sold under similar branding.
Is this advice to take either?
No. Education only.
Uncertainty flags
- Overlap in secondary effects (mood, attention under stress) can blur categories in anecdotes.
- English-language coverage is thin relative to Russian primary literature; translation and selection bias are real.
- Trial designs for both often fall short of contemporary Western Phase 3 expectations.
- Product authenticity outside regulated pharmacies is a separate, major confounder.
- SCIRP / regional journals vary in editorial standards; prefer PubMed-indexed clinical papers and official labels when claims get strong.
Sources
- Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience & Medicine. 2013;4:223-252. doi:10.4236/nm.2013.44035 / PDF: cornerstone comparative review from IMG authors (Semax ACTH line; Selank tuftsin line; Russian clinical framing).
- Kost NV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180-183. PubMed PMID: 11443939.
- Dolotov OV, et al. Semax… regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117:54-60. PMID: 16996037.
- Gusev EI, et al. Effectiveness of semax in acute hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472.
- Gusev EI, et al. Efficacy of semax at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68. PMID: 29798983.
- Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096.
- Volkova A, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016. PMID: 26924987 / PMC4757669.
- Official Semax Russian prescribing text (identity / prescription nasal product): ЛС-002553 package insert PDF.
- Background secondary overview: Wikipedia: Semax.